Last edition
News about "TEMPO clinical trial"
US FDA Approves AbbVie's JUVMO for Parkinson's Disease
The US FDA has approved AbbVie’s JUVMO (tavapadon) for Parkinson’s Disease (PD), supported by phase 3 TEMPO data showing improved daily function.
TEMPO Clinical Trial | 30/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members